NCT00337259View on ClinicalTrials.gov

Gemcitabine for Marginal Zone Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Non-Hodgkin's LymphomaMarginal Zone Lymphoma
Interventions
DRUG

gemcitabine

D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Asan Medical Center

OTHER